Please check your internet connection and try again.
# Ticagrelor
## Overview
Ticagrelor is an orally administered, direct-acting, reversible P2Y12 receptor antagonist. It is a member of the cyclopentyltriazolopyrimidine (CPTP) class.
## Primary Indications
* **Acute Coronary Syndromes (ACS):** To reduce the rate of thrombotic cardiovascular events (including stent thrombosis) in patients with ACS, managed with percutaneous coronary intervention (PCI).
* **Myocardial Infarction (MI):** In patients with a history of MI, ticagrelor is indicated to reduce the rate of cardiovascular death, myocardial infarction, and stroke.
## Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily.
* **History of MI:**
* **Maintenance Dose:** 60 mg orally twice daily.
* **Duration of therapy:** In ACS, typically continued for at least 12 months. In patients with a history of MI, may be continued long-term.
## Pediatric Dosing
* Ticagrelor is not recommended for use in pediatric patients.
## Dose Adjustments
* **Renal Impairment:** No dose adjustment is needed in patients with mild, moderate, or severe renal impairment.
* **Hepatic Impairment:** No dose adjustment is needed in patients with mild to moderate hepatic impairment. Use with caution in severe hepatic impairment.
## Contraindications
* Active pathological bleeding (e.g., peptic ulcer, intracranial hemorrhage).
* History of transient ischemic attack or stroke.
* Concomitant use of strong CYP3A4 inhibitors.
* Known hypersensitivity to ticagrelor or any of its excipients.
## Adverse Effects
* **Most Common:** Dyspnea, bruising, bleeding (including major and minor).
* **Serious:** Major bleeding, intracranial hemorrhage, severe dyspnea, bradyarrhythmia.
* **Other:** Ventricular pauses, hyperuricemia, elevated creatinine.
## Key Drug Interactions
* **CYP3A4 Substrates:** Ticagrelor is a moderate inhibitor of CYP3A4. Concomitant use with strong CYP3A4 substrates (e.g., simvastatin, lovastatin, atorvastatin) may increase exposure to these drugs; consider dose reduction of the statin or alternative statin.
* **CYP3A4 Inhibitors:** Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin, ritonavir) is contraindicated due to increased ticagrelor exposure.
* **CYP3A4 Inducers:** Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin) may decrease ticagrelor exposure and efficacy.
* **Antithrombotics:** Increased risk of bleeding when used with other antithrombotic agents, including anticoagulants, other P2Y12 inhibitors, and NSAIDs.
## Monitoring
* Assess for signs and symptoms of bleeding.
* Monitor for dyspnea.
* Periodically assess renal function.
## Clinical Pearls
* Ticagrelor's onset of action is rapid, and its effect is reversible, although reversibility may not be complete and immediate.
* Dyspnea is a common side effect and is generally not indicative of underlying pulmonary disease. It typically resolves with continued therapy.
* Discontinuation of ticagrelor prematurely increases the risk of thrombotic events, especially in patients with ACS.
***
*Disclaimer: This information is intended for clinical use and does not replace professional judgment. Always consult the official prescribing information for the most current and complete details.*
